Abstract
Objective To evaluate the clinical therapeutic effects and safety of trimetazidine(TMZ) in patients with coronary heart disease(CHD)and chronic heart failure(CHF). Methods 114 patients with CHD and CHF were randomly divided into treatment group 50 cases and the control group 64 cases. The control group was given conventional anti-heart failure therapy; The treatment group were given 20 mg trimetazidine (3 times per day) on the basis of conventional therapy of the control group. The course of treatment all were 6 months in 2Groups. Clinical efficacy, left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) ,serum B-type natriuretic peptide(BNP) ,6 min walk test,and adverse drug reactions were observed before and 6 months after therapy. Results After treatment for 6 months, the total effective rate of the treatment group was significantly higher than that of the control group( P ＜ 0.05 ); The LVEDd, LVEF, 6-minute walking distance and the level of BNP in the treatment group improved significantly better than that of the control group ( P ＜ 0.05 ); the treatment group occurred few and mild adverse drug reactions. Conclusion Long-term use trimetazidine treating in patients with with CHD and CHF can improve cardiac function, safe and effective. Key words: Coronary heart disease; Chronic heart failure; Trimetazidine
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
